[1]
|
NCCN. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version 2[EB/OL ]. [2020-09-16]. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. |
[2]
|
NCCN. Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 2[EB/OL ]. [2020-09-16]. https://www.nccn.org/professionals/physician_gls/pdf/kidney_blocks.pdf. |
[3]
|
Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors[J]. Cancer, 2008, 113: 5-21. doi: 10.1002/cncr.23542 |
[4]
|
王彦卿, 陈野野, 黄诚, 等. 肺类癌的诊治进展[J]. 协和医学杂志, 2021, 12: 366-372. doi: 10.3969/j.issn.1674-9081.2020.00.006
Wang YQ, Cheng YY, Huang C, et al. Progress in the Diagnosis and Treatment of Pulmonary Carcinoids[J]. Xiehe Yixue Zazhi, 2021, 12: 366-372. doi: 10.3969/j.issn.1674-9081.2020.00.006 |
[5]
|
Walts AE, Ines D, Marchevsky AM. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors[J]. Mod Pathol, 2012, 25: 1258-1264. doi: 10.1038/modpathol.2012.81 |
[6]
|
沈松杰, 韩志军, 于双妮, 等. 乳腺癌合并恶性肺结节: 乳腺癌肺转移? 还是乳腺和肺双原发癌?[J]. 协和医学杂志, 2019, 11: 109-114. doi: 10.3969/j.issn.1674-9081.20190116
Shen SJ, Han ZJ, Yu SN, et al. Breast cancer combined with malignant pulmonary nodules: pulmonary metastases from breast cancer? or breast and lung metastases?[J]. Xiehe Yixue Zazhi, 2019, 11: 109-114. doi: 10.3969/j.issn.1674-9081.20190116 |
[7]
|
Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30: 706-720. doi: 10.1093/annonc/mdz056 |
[8]
|
Noronha V, Joshi A, Bakshi G, et al. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma[J]. Indian J Cancer, 2016, 53: 102-108. doi: 10.4103/0019-509X.180824 |
[9]
|
Suarez-Sarmiento A Jr, Nguyen KA, Syed JS, et al. Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study[J]. Clin Genitourin Cancer, 2019, 17: e1163-e1170. doi: 10.1016/j.clgc.2019.08.006 |
[10]
|
Bellesoeur A, Carton E, Alexandre J, et al. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy[J]. Drug Des Devel Ther, 2017, 11: 2801-2811. doi: 10.2147/DDDT.S109640 |
[11]
|
Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14: 552-562. doi: 10.1016/S1470-2045(13)70093-7 |
[12]
|
Kim YH, Kim JW, Chung HT, et al. Brain metastasis from renal cell carcinoma[J]. Prog Neurol Surg, 2012, 25: 163-175. doi: 10.1159/000331190 |
[13]
|
Fokas E, Henzel M, Hamm K, et al. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients[J]. Strahlenther Onkol, 2010, 186: 210-217. doi: 10.1007/s00066-010-2055-z |
[14]
|
Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma[J]. Eur Urol, 2019, 75: 74-84. doi: 10.1016/j.eururo.2018.08.036 |
[15]
|
Daugherty M, Daugherty E, Jacob J, et al. Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy[J]. Urol Oncol, 2019, 37: 182. e9-182. e15. doi: 10.1016/j.urolonc.2018.10.021 |
[16]
|
de Sousa VML, Carvalho L. Heterogeneity in Lung Cancer[J]. Pathobiology, 2018, 85: 96-107. doi: 10.1159/000487440 |
[17]
|
Sellner F. Isolated Pancreatic Metastases of Renal Cell Carcinoma-A Paradigm of a Seed and Soil Mechanism: A Literature Analysis of 1, 034 Observations[J]. Front Oncol, 2020, 10: 709. doi: 10.3389/fonc.2020.00709 |
[18]
|
Turajlic S, Xu H, Litchfield K, et al. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal[J]. Cell, 2018, 173: 581-594. e12. doi: 10.1016/j.cell.2018.03.057 |
[19]
|
Daboul N, Monga D, Bunker M. Primary renal carcinoid tumour with lung metastasis misdiagnosed as renal cell carcinoma[J]. BMJ Case Rep, 2016, 2016: bcr2015213432. http://www.ncbi.nlm.nih.gov/pubmed/26951438 |
[20]
|
Gill DM, Hahn AW, Hale P, et al. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma[J]. Curr Treat Options Oncol, 2018, 19: 6. doi: 10.1007/s11864-018-0517-1 |
[21]
|
Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study[J]. Lancet Oncol, 2013, 14: 141-148. doi: 10.1016/S1470-2045(12)70559-4 |
[22]
|
Escudier B, Motzer RJ, Tannir NM, et al. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214[J]. Eur Urol, 2020, 77: 449-453. doi: 10.1016/j.eururo.2019.10.025 |
[23]
|
Lara P, Todd MB, Hamid O, et al. Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase Ⅰ/Ⅱ results from ECHO-202/KEYNOTE-037[J]. Clin Oncol, 2017, 35: 4515. http://www.researchgate.net/publication/345682256_Epacadostat_plus_pembrolizumab_in_patients_with_advanced_RCC_Preliminary_phase_III_results_from_ECHO-202KEYNOTE-037 |
[24]
|
Monteiro FSM, Soares A, Debiasi M, et al. First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis[J]. Clin Genitourin Cancer, 2020, 18: 244-251. e4. http://www.sciencedirect.com/science/article/pii/S155876732030046X |
[25]
|
Siam L, Bleckmann A, Chaung HN, et al. The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study[J]. Oncotarget, 2015, 6: 29254-29267. doi: 10.18632/oncotarget.4201 |
[26]
|
Suh JH, Kotecha R, Chao ST, et al. Current approaches to the management of brain metastases[J]. Nat Rev Clin Oncol, 2020, 17: 279-299. http://www.nature.com/articles/s41571-019-0320-3 |